早期乳腺癌绝经前女性化疗期间使用GnRH激动剂保留卵巢功能的成本效益分析
该研究从美国 perspective 构建两个决策分析模型,比较化疗期间加用GnRH激动剂(GnRHa)与单纯化疗在预防绝经症状和保留生育力方面的成本效益。结果显示,预防绝经症状时增量成本效果比为每QALY 17900.85美元,低于50000美元/QALY的支付意愿阈值;保留生育力时,体外卵母细胞冻存(OC)组和无OC组的增量成本效果比分别为每活产67933.50美元和60209.00美元。
要点
- 预防绝经症状时,GnRHa加化疗的ICER为每QALY 17900.85美元,低于50000美元/QALY阈值,具成本效益。
- 保留生育力时,OC组和无OC组的ICER分别为每活产67933.50美元和60209.00美元。
- 概率敏感性分析显示预防绝经症状策略具成本效益的概率为81.76%。
核心结论
- 从美国 perspective,化疗期间使用GnRHa预防绝经前乳腺癌患者绝经症状在50000美元/QALY阈值下具成本效益。
- 对于接受或未接受OC的年轻乳腺癌患者,当每活产支付意愿阈值分别为71333.33美元和61920.00美元时,加用GnRHa保留生育力具成本效益。
研究设计与样本
- 研究构建两个决策分析模型,分别针对预防绝经症状和保留生育力,时间跨度为5年。
- 模型比较两种策略:化疗期间加用GnRHa(GnRHa加化疗)与单纯化疗。
- 研究对象为18-49岁接受化疗的早期绝经前乳腺癌女性,数据来源于已发表文献和官方网站。
主要发现
- 在绝经症状模型中,GnRHa加化疗相比单纯化疗的ICER为每QALY 17900.85美元。
- 概率敏感性分析显示GnRHa加化疗策略具成本效益的概率为81.76%。
- 在生育力模型中,接受OC的患者加用GnRHa的ICER为每活产67933.50美元,无法接受OC的患者为每活产60209.00美元。
- 概率敏感性分析表明,在情境I(OC后保留生育力)支付意愿超过71333.33美元/活产、情境II(无法接受OC)超过61920.00美元/活产时,GnRHa加化疗更可能具成本效益。
关键数值与推荐
- 绝经症状模型:GnRHa加化疗的ICER为每QALY 17900.85美元,支付意愿阈值为50000.00美元/QALY。
- 生育力模型:OC组ICER为每活产67933.50美元,无OC组为每活产60209.00美元。
- 概率敏感性分析:绝经症状策略成本效益概率81.76%。
临床怎么用
- 研究结果为临床决策提供基于证据的参考,表明化疗期间使用GnRHa预防绝经症状和保留生育力是值得的。
局限性
- 未纳入间接成本,如疾病相关精神损害和非医疗成本(如交通费用)。
- 所有数据来自已发表文献和数据库,可能与真实世界存在差异。
- 绝经症状模型未考虑发生率较低的POI所致绝经症状及具体化疗方案。
- 生育力模型中5年生育时间跨度可能不适用于所有患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is it economically worthwhile to use GnRH agonist (GnRHa) to prevent menopausal symptoms (MS) and protect fertility in premenopausal women with breast cancer (BC) during chemotherapy from the US perspective? SUMMARY ANSWER: It is cost-effective to administer GnRHa during chemotherapy in order to forefend MS in premenopausal patients with BC when the willingness-to-pay (WTP) threshold is $50 000.00 per quality-adjusted life-year (QALY), and to preserve fertility in young patients with BC who undergo oocyte cryopreservation (OC), or no OC, when the WTP thresholds per live birth are $71 333.33 and $61 920.00, respectively. WHAT IS KNOWN ALREADY: Chemotherapy often results in premature ovarian insufficiency (POI) in premenopausal survivors of BC, causing MS and infertility. Administering GnRHa during chemotherapy has been recommended for ovarian function preservation by international guidelines. STUDY DESIGN, SIZE, DURATION: Two decision-analytic models were developed, respectively, for preventing MS and protecting fertility over a 5-year period, which compared the cost-effectiveness of two strategies: adding GnRHa during chemotherapy (GnRHa plus Chemo) or chemotherapy alone (Chemo). PARTICIPANTS/MATERIALS, SETTING, METHODS: The participants were early premenopausal women with BC aged 18-49 years who were undergoing chemotherapy. Two decision tree models were constructed: one for MS prevention and one for fertility protection from the US perspective. All data were obtained from published literature and official websites. The models' primary outcomes included QALYs and incremental cost-effectiveness ratios (ICERs). The robustness of the models was tested by sensitivity analyses. MAIN RESULTS AND THE ROLE OF CHANCE: In the MS model, GnRHa plus Chemo resulted in an ICER of $17 900.85 per QALY compared with Chemo, which was greater than the WTP threshold of $50 000.00 per QALY; therefore, GnRHa plus Chemo was a cost-effective strategy for premenopausal women with BC in the USA. Probabilistic sensitivity analysis (PSA) results showed an 81.76% probability of cost-effectiveness in the strategy. In the fertility model, adding GnRHa for patients undergoing OC and those who were unable to undergo OC resulted in ICERs of $67 933.50 and $60 209.00 per live birth in the USA, respectively. PSA indicated that GnRHa plus Chemo was more likely to be cost-effective over Chemo when the WTP for an additional live birth exceed $71 333.33 in Context I (adding GnRHa to preserve fertility in young patients with BC after OC) and $61 920.00 in Context II (adding GnRHa to preserve fertility in young patients with BC who cannot accept OC). LIMITATIONS, REASONS FOR CAUTION: The indirect costs, such as disease-related mental impairment and non-medical costs (e.g. transportation cost) were not included. All data were derived from previously published literature and databases, which might yield some differences from the real world. In addition, the POI-induced MS with a lower prevalence and the specific strategy of chemotherapy were not considered in the MS model, and the 5-year time horizon for having a child might not be suitable for all patients in the fertility model. WIDER IMPLICATIONS OF THE FINDINGS: When considering the economic burden of cancer survivors, the results of this study provide an evidence-based reference for clinical decision-making, showing that it is worthwhile to employ GnRHa during chemotherapy to prevent MS and preserve fertility. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Natural Science Foundation of Fujian Province [2021J02038]; and the Startup Fund for Scientific Research, Fujian Medical University [2021QH1059]. All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Huang Y, Huang X, Huang X, et al. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer. Hum Reprod. 2023. PMID: 37075316. doi:10.1093/humrep/dead073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。